Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Fibroblast growth factor 21202 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A18654 | 27012627 | J Nutr Biochem | Hydroxytyrosol prevents metabolic impairment reducing hepatic inflammation and restoring duodenal integrity in a rat model of NAFLD. | 2016 | Details |
| A18739 | 26977393 | Mol Metab | Acyl CoA synthetase 5 (ACSL5) ablation in mice increases energy expenditure and insulin sensitivity and delays fat absorption. | 2016 | Details |
| A18810 | 26926384 | Hepatology | Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice. | 2016 | Details |
| A18976 | 26838599 | Gut | Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. | 2016 | Details |
| A19272 | 26663034 | Acta Physiol (Oxf) | Gastric bypass surgery is protective from high-fat diet-induced non-alcoholic fatty liver disease and hepatic endoplasmic reticulum stress. | 2015 | Details |
| A19641 | 26441837 | Front Endocrinol (Lausanne) | Research Perspectives on the Regulation and Physiological Functions of FGF21 and its Association with NAFLD. | 2015 | Details |
| A19982 | 26226139 | PLoS One | Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial. | 2015 | Details |
| A20017 | 26203166 | J Endocrinol | Hepatic insulin resistance and increased hepatic glucose production in mice lacking Fgf21. | 2015 | Details |
| A20046 | 26192240 | Zhonghua Gan Zang Bing Za Zhi | [A prospective study of serum fibroblast growth factor 21 changes in nonalcoholic fatty liver patients]. | 2015 | Details |
| A20152 | 26121037 | PLoS One | Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis. | 2015 | Details |
| A20316 | 26032587 | Pharmacol Res | Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial. | 2015 | Details |
| A20615 | 25850006 | Cardiovasc Diabetol | Serum fibroblast growth factor 21 levels is associated with lower extremity atherosclerotic disease in Chinese female diabetic patients. | 2015 | Details |
| A20784 | 25736301 | Biochim Biophys Acta | Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet. | 2015 | Details |
| A20796 | 25729707 | Diabetes Metab J | Hepatokines as a Link between Obesity and Cardiovascular Diseases. | 2015 | Details |
| A20803 | 25727012 | Biochem Biophys Res Commun | Endoplasmic reticulum stress induces up-regulation of hepatic β-Klotho expression through ATF4 signaling pathway. | 2015 | Details |
| A21004 | 25583095 | Clin Biochem | Laboratory assessment of cardiometabolic risk in overweight and obese children. | 2015 | Details |
| A21012 | 25577300 | Dig Liver Dis | Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. | 2014 | Details |
| A21097 | 25537833 | Diabetologia | Fibroblast growth factor 21 participates in adaptation to endoplasmic reticulum stress and attenuates obesity-induced hepatic metabolic stress. | 2014 | Details |
| A21143 | 25516477 | Metabolism | The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy. | 2014 | Details |
| A21379 | 25359230 | J Nutrigenet Nutrigenomics | The single nucleotide polymorphism rs499765 is associated with fibroblast growth factor 21 and nonalcoholic fatty liver disease in a Chinese population with normal glucose tolerance. | 2014 | Details |
| A21445 | 25312648 | Mol Cell Biol | Hepatic mitogen-activated protein kinase phosphatase 1 selectively regulates glucose metabolism and energy homeostasis. | 2014 | Details |
| A21629 | 25170079 | J Biol Chem | Fibroblast growth factor 21 is regulated by the IRE1α-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis. | 2014 | Details |
| A21733 | 25083607 | Gastroenterology | Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. | 2014 | Details |
| A22001 | 24900988 | Biomed Res Int | ATF4- and CHOP-dependent induction of FGF21 through endoplasmic reticulum stress. | 2014 | Details |
| A22290 | 24689234 | Yao Xue Xue Bao | [Therapeutic effect of fibroblast growth factor 21 on NAFLD in MSG-iR mice and its mechanism]. | 2013 | Details |
| A22368 | 24634829 | Mol Metab | Tissue-selective estrogen complexes with bazedoxifene prevent metabolic dysfunction in female mice. | 2014 | Details |
| A23181 | 23981342 | Cardiovasc Diabetol | Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. | 2013 | Details |
| A23535 | 23702383 | Metabolism | Artemisia scoparia extract attenuates non-alcoholic fatty liver disease in diet-induced obesity mice by enhancing hepatic insulin and AMPK signaling independently of FGF21 pathway. | 2013 | Details |
| A24182 | 23142063 | J Hepatol | High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China. | 2012 | Details |
| A24194 | 23134073 | Clin Endocrinol (Oxf) | Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. | 2013 | Details |
| A24206 | 23123503 | Biochimie | Fibroblast growth factor 21 is induced by endoplasmic reticulum stress. | 2012 | Details |
| A24341 | 22985537 | Clin Chim Acta | Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis. | 2012 | Details |
| A24440 | 22891896 | Appl Physiol Nutr Metab | Modulating fibroblast growth factor 21 in hyperphagic OLETF rats with daily exercise and caloric restriction. | 2012 | Details |
| A24840 | 22438225 | J Clin Endocrinol Metab | Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. | 2012 | Details |
| A24956 | 22314419 | J Hepatol | Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. | 2012 | Details |
| A25074 | 22190000 | Eur J Endocrinol | Decrease in circulating fibroblast growth factor 21 after an oral fat load is related to postprandial triglyceride-rich lipoproteins and liver fat. | 2011 | Details |
| A25323 | 21956711 | Diabetologia | Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. | 2011 | Details |
| A25336 | 21949781 | PLoS One | Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study. | 2011 | Details |
| A25557 | 21713513 | Appl Microbiol Biotechnol | Large-scale expression, purification, and glucose uptake activity of recombinant human FGF21 in Escherichia coli. | 2011 | Details |
| A26005 | 21216282 | Biochim Biophys Acta | Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease. | 2011 | Details |
| A26304 | 20675007 | J Hepatol | Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. | 2010 | Details |
| A26345 | 20624171 | Eur J Clin Invest | Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. | 2010 | Details |
| A26461 | 20451522 | Gastroenterology | Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. | 2010 | Details |
| A26543 | 20236931 | J Biol Chem | Thyroid hormone regulates hepatic expression of fibroblast growth factor 21 in a PPARalpha-dependent manner. | 2010 | Details |
| A28725 | 35092323 | J Magn Reson Imaging | Evaluation of a PEGylated Fibroblast Growth Factor 21 Variant Using Novel Preclinical Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Mouse Model of Nonalcoholic Steatohepatitis. | 2022 | Details |
| A28960 | 34773249 | Br J Pharmacol | Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats. | 2022 | Details |
| A29227 | 34386991 | J Labelled Comp Radiopharm | Synthesis of tritium labeled 30-KDa PEG and conjugation to form [3 H]Pegbelfermin. | 2021 | Details |
| A29244 | 34364948 | Toxicol Appl Pharmacol | Pegbelfermin, a PEGylated FGF21 analogue, has pharmacology without bone toxicity after 1-year dosing in skeletally-mature monkeys. | 2021 | Details |
| A30237 | 32764725 | Nat Rev Endocrinol | The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. | 2020 | Details |
| A31161 | 31120771 | FASEB J | Betaine attenuates pathology by stimulating lipid oxidation in liver and regulating phospholipid metabolism in brain of methionine-choline-deficient rats. | 2019 | Details |
| A32389 | 28576430 | Drug Discov Today | Gastric bypass surgery mimetic approaches. | 2017 | Details |
| A32463 | 28385694 | Am J Physiol Gastrointest Liver Physiol | Phosphatidylcholine transfer protein/StarD2 promotes microvesicular steatosis and liver injury in murine experimental steatohepatitis. | 2017 | Details |
| A33774 | 25178843 | Biochim Biophys Acta | Role of white adipose lipolysis in the development of NASH induced by methionine- and choline-deficient diet. | 2014 | Details |
| A34229 | 24021426 | J Hepatol | Serum FGF21 increases with hepatic fat accumulation in pediatric onset intestinal failure. | 2013 | Details |
| A35205 | 21448070 | Eur J Gastroenterol Hepatol | Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. | 2011 | Details |
| A42710 | 33681679 | Hepatol Commun | Fatty Acid Desaturase 1 Influences Hepatic Lipid Homeostasis by Modulating the PPARα-FGF21 Axis. | 2020 | Details |
| A43145 | 32431189 | J Am Heart Assoc | Fibroblast Growth Factor 21 is Related to Atherosclerosis Independent of Nonalcoholic Fatty Liver Disease and Predicts Atherosclerotic Cardiovascular Events. | 2020 | Details |
| A43432 | 31728756 | Endocrine | Liver-derived FGF21 is essential for full adaptation to ketogenic diet but does not regulate glucose homeostasis. | 2019 | Details |
| A43591 | 31337282 | Thyroid | A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia. | 2019 | Details |
| A43675 | 31134632 | Hepatology | Is Trimming the Fat Enough? Fibroblast Growth Factor 21 as An Emerging Treatment for Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A43783 | 30890204 | Gene Expr | Sterol 12α-Hydroxylase Aggravates Dyslipidemia by Activating the Ceramide/mTORC1/SREBP-1C Pathway via FGF21 and FGF15. | 2019 | Details |
| A43890 | 30554786 | Lancet | Fibroblast growth factor 21 for non-alcoholic steatohepatitis. | 2018 | Details |
| A44774 | 27351453 | Hepatology | G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice. | 2016 | Details |
| A45349 | 25077735 | Expert Opin Ther Targets | The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target. | 2014 | Details |
| A45397 | 24814977 | J Lipid Res | Fatty acid elongase-5 (Elovl5) regulates hepatic triglyceride catabolism in obese C57BL/6J mice. | 2014 | Details |
| A45545 | 23999826 | Endocr Connect | Increased FGF21 plasma levels in humans with sepsis and SIRS. | 2013 | Details |
| A45586 | 23766126 | Endocrinology | Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. | 2013 | Details |
| A46140 | 20800308 | J Hepatol | Fibroblast growth factor 21 as a biomarker for NAFLD: integrating pathobiology into clinical practice. | 2010 | Details |
| A46909 | 34774847 | Am J Pathol | ZFP36L1 Regulates Fgf21 mRNA Turnover and Modulates Alcoholic Hepatic Steatosis and Inflammation in Mice. | 2021 | Details |
| A46920 | 34265279 | Biochem Pharmacol | PPARα agonist WY-14,643 induces adipose atrophy and fails to blunt chronic ethanol-induced hepatic fat accumulation in mice lacking adipose FGFR1. | 2021 | Details |
| A47094 | 26092866 | J Lipid Res | FGF21 mediates alcohol-induced adipose tissue lipolysis by activation of systemic release of catecholamine in mice. | 2015 | Details |
| A47135 | 25355486 | Acta Biochim Biophys Sin (Shanghai) | FGF21 treatment ameliorates alcoholic fatty liver through activation of AMPK-SIRT1 pathway. | 2014 | Details |
| A47630 | 34732847 | Lab Invest | Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice. | 2021 | Details |
| A48089 | 24424044 | Endocrinology | Liver-enriched transcription factor CREBH interacts with peroxisome proliferator-activated receptor α to regulate metabolic hormone FGF21. | 2014 | Details |
| A48533 | 34616107 | J Clin Biochem Nutr | Spirulina platensis and its ingredient biopterin glucoside improved insulin sensitivity in non-alcoholic steatohepatitis model. | 2021 | Details |
| A48656 | 32195457 | JHEP Rep | miR-22 inhibition reduces hepatic steatosis via FGF21 and FGFR1 induction. | 2020 | Details |
| A48824 | 27498701 | Sci Rep | Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury. | 2016 | Details |
| A48842 | 26797127 | J Biol Chem | Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21. | 2016 | Details |
| A49452 | 35745238 | Nutrients | Effects of Calorie Restricted Diet on Oxidative/Antioxidative Status Biomarkers and Serum Fibroblast Growth Factor 21 Levels in Nonalcoholic Fatty Liver Disease Patients: A Randomized, Controlled Clinical Trial. | 2022 | Details |
| A49473 | 35743140 | Int J Mol Sci | Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis. | 2022 | Details |
| A49534 | 35723052 | Food Funct | Coffee peel extracts ameliorate non-alcoholic fatty liver disease via a fibroblast growth factor 21-adiponectin signaling pathway. | 2022 | Details |
| A49808 | 35630668 | Molecules | Non-Alcoholic Fatty Liver Disease in Long-Term Type 2 Diabetes: Role of rs738409 PNPLA3 and rs499765 FGF21 Polymorphisms and Serum Biomarkers. | 2022 | Details |
| A49851 | 35620160 | Chronic Dis Transl Med | Hepatic hormone FGF21 and its analogues in clinical trials. | 2022 | Details |
| A49895 | 35605662 | J Biol Chem | Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway. | 2022 | Details |
| A49923 | 35594631 | Nutrition | Concentrated fish oil ameliorates non-alcoholic fatty liver disease by regulating fibroblast growth factor 21-adiponectin axis. | 2022 | Details |
| A50381 | 35410857 | Turk J Gastroenterol | Fibroblast Growth Factor 21 as a Marker of Prediabetes in Patients with Non-alcoholic Fatty Liver Disease. | 2022 | Details |
| A50438 | 35392289 | Front Nutr | Activating Effects of the Bioactive Compounds From Coffee By-Products on FGF21 Signaling Modulate Hepatic Mitochondrial Bioenergetics and Energy Metabolism in vitro. | 2022 | Details |
| A50483 | 35368766 | Evid Based Complement Alternat Med | An Open-Label Exploratory Clinical Trial Evaluating the Effects of GLS (Coptidis Rhizoma-Evodiae Fructus 2 : 1) on Fibroblast Growth Factor 21 in Patients with Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A50755 | 35277004 | Nutrients | Fibroblast Growth Factor 19 and Fibroblast Growth Factor 21 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Gastric Bypass. | 2022 | Details |
| A50882 | 34529079 | J Clin Endocrinol Metab | Another Kid on the Block: Long-acting FGF21 Analogue to Treat Dyslipidemia and Fatty Liver. | 2022 | Details |
| A51182 | 35323680 | Metabolites | Plasma Tsukushi Concentration Is Associated with High Levels of Insulin and FGF21 and Low Level of Total Cholesterol in a General Population without Medication. | 2022 | Details |
| A51425 | 35592498 | Mol Ther Nucleic Acids | Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice. | 2022 | Details |
| A51580 | 34889064 | J Diabetes Investig | Circulating level of fatty acid-binding protein 4 is an independent predictor of metabolic dysfunction-associated fatty liver disease in middle-aged and elderly individuals. | 2022 | Details |
| A51779 | 34141520 | Adv Sci (Weinh) | Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus. | 2021 | Details |
| A51867 | 33575433 | Mol Ther Methods Clin Dev | Visceral adipose tissue-directed FGF21 gene therapy improves metabolic and immune health in BTBR mice. | 2020 | Details |
| A51869 | 33556473 | Mol Cell Endocrinol | Pubertal FGF21 deficit is central in the metabolic pathophysiology of an ovine model of polycystic ovary syndrome. | 2021 | Details |
| A51901 | 33347566 | J Clin Endocrinol Metab | Plasma Bile Acids More Closely Align With Insulin Resistance, Visceral and Hepatic Adiposity Than Total Adiposity. | 2021 | Details |
| A51935 | 33083279 | Liver Cancer | Dietary Restriction Suppresses Steatosis-Associated Hepatic Tumorigenesis in Hepatitis C Virus Core Gene Transgenic Mice. | 2020 | Details |
| A51996 | 32512788 | Antioxidants (Basel) | Cold-Pressed Nigella Sativa Oil Standardized to 3% Thymoquinone Potentiates Omega-3 Protection against Obesity-Induced Oxidative Stress, Inflammation, and Markers of Insulin Resistance Accompanied with Conversion of White to Beige Fat in Mice. | 2020 | Details |
| A52131 | 30920846 | Am J Physiol Gastrointest Liver Physiol | Intestinal serine protease inhibition increases FGF21 and improves metabolism in obese mice. | 2019 | Details |